efegatran has been researched along with CAY10435 in 1 studies
| Studies (efegatran) | Trials (efegatran) | Recent Studies (post-2010) (efegatran) | Studies (CAY10435) | Trials (CAY10435) | Recent Studies (post-2010) (CAY10435) |
|---|---|---|---|---|---|
| 43 | 3 | 0 | 5 | 0 | 4 |
| Protein | Taxonomy | efegatran (IC50) | CAY10435 (IC50) |
|---|---|---|---|
| Fatty-acid amide hydrolase 1 | Homo sapiens (human) | 0.0168 | |
| Diacylglycerol lipase-alpha | Homo sapiens (human) | 0.0309 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Costanzo, MJ; Maryanoff, BE | 1 |
1 review(s) available for efegatran and CAY10435
| Article | Year |
|---|---|
Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.
Topics: Amidohydrolases; Enzyme Inhibitors; Heterocyclic Compounds; Humans; Ketones; Protease Inhibitors | 2008 |